Literature DB >> 16503744

BCG immunotherapy--from pathophysiology to clinical practice.

Moshe Tishler1, Yehuda Shoenfeld.   

Abstract

Treatment with Bacillus Calmette-Guérin vaccine is mainly in use for superficial bladder cancer, for which it is given intravesically. Overall, this therapy is safe with only minor side effects. Arthritis secondary to such therapy has been rarely reported and usually responds well to NSAID treatment. The mechanisms leading to such a complication, as well as the clinical data, are discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16503744     DOI: 10.1517/14740338.5.2.225

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  4 in total

1.  Case: Bacillus Calmette-Guerin (BCG)-induced Reiter syndrome with an attempt at repeat BCG induction.

Authors:  Douglas C Cheung; Alexandra L Millman; Robert J Hamilton
Journal:  Can Urol Assoc J       Date:  2017-12-01       Impact factor: 1.862

2.  Specific and randomly derived immunoactive peptide mimotopes of mycobacterial antigens.

Authors:  Archna Sharma; Abhik Saha; Surajit Bhattacharjee; Subrata Majumdar; Sujoy K Das Gupta
Journal:  Clin Vaccine Immunol       Date:  2006-08-17

Review 3.  Rebuilding immunity in cancer patients.

Authors:  Stanimir Vuk-Pavlovic
Journal:  Blood Cells Mol Dis       Date:  2007-09-10       Impact factor: 3.039

4.  Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF.

Authors:  Angelo Corti; Monica Giovannini; Carmen Belli; Eugenio Villa
Journal:  J Oncol       Date:  2010-06-03       Impact factor: 4.375

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.